| [Clostridium] polysaccharolyticum| ATCC 33142| Clostridium polysaccharolyticum| Clostridium polysaccharolyticum (van Gylswyk 1981) van Gylswyk et al. 1983| DSM 1801| Fusobacterium polysaccharolyticum| Fusobacterium polysaccharolyticum van Gylswyk 1981| strain B
Gut microbiota: Clostridium species are commonly found in the human gut microbiota, where they play important roles in fermentation, metabolism, and immune regulation. While some Clostridium species are considered beneficial and contribute to gut health, others may be opportunistic pathogens under certain conditions. Clostridium difficile, for example, is a well-known pathogen that can cause antibiotic-associated diarrhea and pseudomembranous colitis.
Fermentation and metabolism: Clostridium polysaccharolyticum, like other members of the genus, is capable of fermenting complex carbohydrates, such as polysaccharides, into simpler compounds like short-chain fatty acids (SCFAs) and gases. These metabolic byproducts can have diverse effects on host physiology, immune function, and gut barrier integrity.
Pathogenicity: While Clostridium polysaccharolyticum is not commonly associated with human disease, some Clostridium species are known to produce toxins and enzymes that can cause illness in humans. Clostridium botulinum produces botulinum toxin, which can cause botulism, a severe and potentially life-threatening illness characterized by muscle weakness, paralysis, and respiratory failure. Clostridium perfringens produces toxins that can cause gas gangrene, necrotizing enteritis, and food poisoning.
Opportunistic infections: Clostridium species, including Clostridium polysaccharolyticum, have been implicated in opportunistic infections, particularly in healthcare settings. Infections with Clostridium species can occur following surgical procedures, invasive medical interventions, or prolonged antibiotic therapy. Clostridium difficile infections, in particular, have become a significant public health concern due to the emergence of antibiotic-resistant strains and the associated morbidity and mortality.
Potential probiotic properties: While most research on Clostridium species has focused on their pathogenic potential, some strains may have probiotic properties and could be beneficial for gut health. Clostridium species capable of producing SCFAs, such as butyrate, may have anti-inflammatory and immunomodulatory effects in the gut. However, further research is needed to evaluate the safety and efficacy of Clostridium-based probiotics for human use.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 0.44 | 30 | 2426 | 0 | 1785 | 332.8 | 65 | 740.9 | 30 | 2426 | 8.3 %ile | 83.3 %ile | ||
thryve | 84.66 | 0 | 328 | 41 | 526 | 0 | 4675 | 494.9 | 140 | 2132.7 | 0 | 590 | 11.9 %ile | 90.3 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSightRdp | 15.625 % | 0.01 % | 0.009 % | 5.0 | 32 |
custom | 5.085 % | 0.084 % | 0.138 % | 3.0 | 59 |
SequentiaBiotech | 2.778 % | 0.027 % | % | 1.0 | 36 |
Thryve | 86.045 % | 0.046 % | 0.197 % | 1190.0 | 1383 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.